Program
zeprumetostat
Also written as “SHR2554”, “TLN-254” and “SHR2554 Tablets”.
Its studies are mostly in Lymphoma · Neoplasms · Prostatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 166 open or running | phase 3since Nov 5, 2023 | Jul 10, 2018 | Apr 2027phase 2 · NCT06368167 |
| Treeline Biosciences | 11 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jul 10, 2018.
- Sep 24, 2020Phase 1 study in HealthyJiangsu HengRui Medicine · NCT04577885 · 18 enrolled · China
- Oct 27, 2020Phase 1 study in Healthy Adult SubjectsJiangsu HengRui Medicine · NCT04627129 · 18 enrolled · China
- Sep 9, 2021Phase 1 study in LymphomaJiangsu HengRui Medicine · NCT05049083 · 28 enrolled · China
- Oct 20, 2022Phase 1 study in NeoplasmsJiangsu HengRui Medicine · NCT05592262 · 20 enrolled · China
- Dec 15, 2022Phase 1 study in NeoplasmsJiangsu HengRui Medicine · NCT05661591 · 18 enrolled · China
- Aug 20, 2023Phase 1 study in LymphomaJiangsu HengRui Medicine · NCT06010680 · 6 enrolled · China
- Oct 17, 2023Phase 1 study in NeoplasmsJiangsu HengRui Medicine · NCT06093945 · 20 enrolled · China
- Nov 5, 2023Phase 3 study in RecurrenceJiangsu HengRui Medicine · NCT06122389 · 130 planned · China
- Dec 8, 2023Phase 2 study in Lymphoma, T-Cell, PeripheralJiangsu HengRui Medicine · NCT06173999 · 100 planned · China
- Apr 11, 2024Phase 2 study in Lymphoma, FollicularJiangsu HengRui Medicine · NCT06368167 · 105 planned · China
- Dec 10, 2024Treeline Biosciences's first study: phase 1 study in LymphomaNew to Treeline BiosciencesTreeline Biosciences · NCT06733441 · 50 enrolled · United States, Canada
- Jul 29, 2025Phase 2 study in Stomach NeoplasmsJiangsu HengRui Medicine · NCT07102901 · 351 planned · China
- Sep 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07175220 · 200 planned · China
- Nov 13, 2025Phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT07230106 · 218 planned · China
Ahead
- Nov 15, 2026Primary completion: phase 1 study in LymphomaTreeline Biosciences · NCT06733441
- Apr 2027Primary completion: phase 2 study in Lymphoma, FollicularJiangsu HengRui Medicine · NCT06368167
- Dec 2027Primary completion: phase 2 study in Stomach NeoplasmsJiangsu HengRui Medicine · NCT07102901
- Oct 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07175220
TargetBeta
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule
Other programs on EZH2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mevrometostat | Pfizer | phase 3 | 7 |
| TR115rule | tarapeutics-science-inc | phase 3 | 3 |
| tulmimetostat | Novartis | phase 2 | 3 |
| EZH1/2 Inhibitor HH2853rule | Haihe Biopharma | phase 2 | 2 |
| valemetostatrule | Daiichi Sankyo | phase 1 | 1 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07230106Prostatic Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2028 | 218 |
| NCT07175220Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jiangsu HengRui Medicine | Oct 2028 | 200 |
| NCT07102901Stomach Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2027 | 351 |
| NCT06733441Lymphoma · United States, Canada | 1 | Active, not recruiting | Treeline Biosciences | Nov 15, 2026 | 50 |
| NCT06368167Lymphoma, Follicular · China | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Apr 2027 | 105 |
| NCT06173999Lymphoma, T-Cell, Peripheral · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 31, 2025 | 100 |
| NCT06122389Recurrence · China | 3 | Recruiting | Jiangsu HengRui Medicine | May 2026 | 130 |
| NCT06093945Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Nov 29, 2023 | 20 |
| NCT06010680Lymphoma · China | 1 | Completed | Jiangsu HengRui Medicine | Nov 27, 2023 | 6 |
| NCT05661591Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Mar 31, 2023 | 18 |
| NCT05592262Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Dec 14, 2022 | 20 |
| NCT05049083Lymphoma · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jan 6, 2022 | 28 |
| NCT04627129Healthy Adult Subjects · China | 1 | Completed | Jiangsu HengRui Medicine | Oct 1, 2020 | 18 |
| NCT04577885Healthy · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 30, 2020 | 18 |
| NCT04335266Healthy Adult Subjects · China | 1 | Completed | Jiangsu HengRui Medicine | Sep 9, 2019 | 20 |
| NCT03741712Prostatic Neoplasms · China | 2 | Terminated | Jiangsu HengRui Medicine | Sep 30, 2019 | 9 |
| NCT03603951Recurrence · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Feb 14, 2026 | 272 |
How it is read
Names in the registry
- “SHR2554”, 6 entries
- “TLN-254”, 2 entries
- “SHR2554 Tablets”, 2 entries
- “SHR2554 Tablet”, 1 entry
- “SHR2554; Chidamide analog tablets”, 1 entry
Codes read as this program: SHR2554.
Conditions, from the studies’ own filings
- Lymphoma, 3 studies
- Neoplasms, 3 studies
- Prostatic Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.